Team awarded $1.2M in funding from NIH
The ability to provide real-time information about an individual's response to therapeutics has the potential to revolutionize healthcare by offering personalized treatment. Drugs with narrow therapeutic windows become toxic or ineffective if over- or under-dosed. Maintaining the most efficient dosage, personalized to the patient, can reduce toxicity, maximize efficacy of treatment, and ultimately improve patient outcome.
In order to address this need, Jennie Leach and Ryan White (UMBC Chemistry) are developing a new class of electrochemical biosensors capable of providing continuous real-time therapeutic drug monitoring with unprecedented chemical specificity and temporal resolution. This project leverages state-of-the-art bioanalytical science (White Lab) with biocompatible material engineering (Leach Lab) to develop hybrid aptamer-hydrogel sensors capable of real-time continuous therapeutic drug monitoring in patients. This work was recently funded by the NIH.
In order to address this need, Jennie Leach and Ryan White (UMBC Chemistry) are developing a new class of electrochemical biosensors capable of providing continuous real-time therapeutic drug monitoring with unprecedented chemical specificity and temporal resolution. This project leverages state-of-the-art bioanalytical science (White Lab) with biocompatible material engineering (Leach Lab) to develop hybrid aptamer-hydrogel sensors capable of real-time continuous therapeutic drug monitoring in patients. This work was recently funded by the NIH.
Read more below!
Posted: January 4, 2016, 7:32 PM
